Imprimis CEO Mark Baum told Business Insider that the reason he wanted to start providing this compound at such a lower cost is because he's worked with the people affected by potential shortages of this drug for years.
"I've served this patient population for a long time, and when I see a company do this … it just shocks the conscience," he said.
あちらの記事 (スコア:3)
サンフランシスコ・クロニクルの姉妹サイトが報じてました。
There's now a $1-a-pill competitor to pharma CEO Martin Shkreli's $750-a-pill drug
http://www.sfgate.com/technology/businessinsider/article/There-s-now-a... [sfgate.com]
Imprimis CEO Mark Baum told Business Insider that the reason he wanted to start providing this compound at such a lower cost is because he's worked with the people affected by potential shortages of this drug for years.
"I've served this patient population for a long time, and when I see a company do this … it just shocks the conscience," he said.
--------------------
/* SHADOWFIRE */
Re:あちらの記事 (スコア:1)
これによると新しい薬の会社は「薬の形状を変える(錠剤を粉薬・飲み薬に変える等)」ことをビジネスにしているみたいですね。
通常はFDA認可済みの成分を購入して再販しているわけですが、今回は既存のFDA認可済みの薬の成分的完全コピーを作ることによって
FDA認可手続きを省略するつもりの様子です。